Dynavax Technologies reported $32.86M in Net Income for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Abbvie ABBV:US $ 4490M 446M
Adma Biologics ADMA:US $ -25.01M 8.36M
Agenus AGEN:US $ -48.32M 17.19M
Amgen AMGN:US $ 1476M 423M
AstraZeneca AZN:LN 386M 733M
Astrazeneca AZN:US $ 386M 733M
Biogen BIIB:US $ 303.8M 64.4M
Biomarin Pharmaceutical BMRN:US $ 120.8M 178.7M
Bristol Myers Squibb BMY:US $ 1278M 1094M
Chimerix CMRX:US $ -24.77M 14.73M
Dynavax Technologies DVAX:US $ 32.86M 66.92M
Gilead Sciences GILD:US $ 19M 363M
Glaxosmithkline GSK:US $ 1802M 1053M
Idera Pharmaceuticals IDRA:US $ -4.18M 0.06M
Merk MRK:US $ 4310M 552M
Minerva Neurosciences NERV:US $ -9.76M 11.54M
Nektar Therapeutics NKTR:US $ -90.39M 55.25M
Neurocrine Biosciences NBIX:US $ 13.9M 21.2M
Novartis NOVN:VX SF 2222M 14086M
Pfizer PFE:US $ 7863M 4470M
Regeneron Pharmaceuticals REGN:US $ 973.5M 1255.5M
Sarepta Therapeutics SRPT:US $ -105.02M 16.96M
Tg Therapeutics TGTX:US $ -69.01M 24.32M
Vertex Pharmaceuticals VRTX:US $ 762.1M 8.01M